Organicell Regenerative Medicine, Inc. Closes $5.5M Funding Round

0

MIAMI, FL/ACCESSWIRE/August 26, 2022/ Organicell Regenerative Medicine, Inc.. (OTCQB:OCEL), a clinical-stage biopharmaceutical company primarily focused on the development of innovative regenerative medicine and biological therapies, has closed its previously announced $4.0 million capital raise at $0.02 and its transaction corporate restructuring. Organicell also closed an additional $1.5 million in funding at $0.04 per share from two additional investors, for total funding of $5.5 million.

This capital injection will allow Organicell to develop its technology platforms for more efficient operations, allow the company to advance its clinical trials and vertically integrate new activities essential to production. Organicell’s investors and Board of Directors strategically represent key pillars of the Company’s new business plan.

Investors Greyt Ventures, LLC and Skycrest Holdings, LLC have asked Bob Smoley, the spouse of the director of Greyt Ventures, to act as an advisor to Organicell throughout its growth phase. Mr. Smokey founded MDLivea telehealth platform, sold to Cignafor $2 billion in April 2021. Organicell sees Mr. Smoley’s extensive network and experience in technology and healthcare as helpful in building Organicell’s new foundation.

Given Mr. Smoley’s involvement with the Company’s Board, the Company and Mr. Smoley have chosen to disclose that Mr. Smoley pleaded guilty to felony charges over a decade ago and served a brief prison camp sentence.

Mr. Smoley is a philanthropic member of his community, a devoted husband and father, and considered a visionary in the healthcare and technology sectors.

The CEO of Organicell issued the following statement:

“It’s easy to pass judgment and put a label on someone… I was responsible for that myself.

Over the past two months I have come to know Bob Smoley on a personal level. I saw his work ethic, his family dynamics and how well regarded he is among his peers.

In human experience, people make mistakes. Sometimes things happen to people for reasons beyond their control. That said, I believe a person shouldn’t be defined by their mistakes or misfortunes, but by how they overcome them.

Bob has extraordinary vision, an incredible network of highly successful friends, and the business acumen to compete at the highest level. Bob’s presentations ultimately helped Organicell out of financial trouble. It gave this business a second chance… let’s make this story a second chance.

One cannot change their past, they can only work to create a new future. For me, experience trumps knowledge and we are lucky to have an advisor who sold a healthcare business for ten digits. Bob’s advice and guidance will be a great asset to our business.

Organicell has opened a new chapter. I’m excited to share further developments as they become relevant.”

About Organicell Regenerative Medicines, Inc.

Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company primarily focused on the development of innovative biological therapies for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain naturally occurring exosomes, hyaluronic acid and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Forward-looking statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act “), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks and uncertainties, and such expectations may prove to be incorrect. We remind you that actual results may vary significantly due to known and unknown risks and uncertainties, including, but not limited to: potential problems with our financial condition, competition, ability to retain personnel key, the safety, efficacy and acceptance of products, the commercial success of any new product or technology, the success of clinical programs, the ability to retain key customers, our inability to expand sales and distribution channels , laws or regulations affecting our operations, including pricing, reimbursement or access to products, the ability to protect our patents and other intellectual property both domestically and internationally, and other risks and known and unknown uncertainties, including risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the W eb of the SEC (http://www.sec.gov ). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. The specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and expressly disclaims any obligation to update the information contained in this press release.

Media Contact:
Joshua Rodriguez
CEO and Founder
CNA Finance, LLC.
(503) 464-6502

THE SOURCE: Organicell Regenerative Medicine

See the source version on accesswire.com:
https://www.accesswire.com/713696/Organicell-Regenerative-Medicine-Inc-Closes-55-Million-Funding-Round

Share.

Comments are closed.